menu search

Aerami therapeutics announces presentation of phase 1 clinical trial data for lead program aer-901 at the 2023 european respiratory society (ers) international congress

DURHAM, N.C., Sept. 12, 2023 (GLOBE NEWSWIRE) — Aerami Therapeutics (“Aerami”), a clinical stage biopharmaceutical company dedicated to breathin...

September 12, 2023, 1:48 pm

Masimo's (masi) pvi favored by study for gdft in elderly patients

Masimo's (MASI) non-invasive, continuous PVi is expected to reduce cardiopulmonary complications and fl...

August 22, 2023, 2:17 pm

Marpai collaborates with nuvoair to offer value-based cardiopulmonary care to self-funded employer health plans

Marpai, Inc. (“Marpai” or the “Company”) (Nasdaq: MRAI), an AI-powered Third-Party Administrator (TPA) transforming self-funded employer healt...

July 5, 2023, 12:29 pm

Bellerophon provides clinical program update and reports first quarter 2023 financial results

Last Patient Completed Blinded Treatment in REBUILD Phase 3 Trial for INOpulse®; Pivotal Top-line Data Expected in Mid-2023 WARREN, N.J., May 15, 202...

May 15, 2023, 8:50 pm

Aerami therapeutics to present pharmacokinetic data supporting aer-901 (inhaled imatinib) for pulmonary hypertension at the 2023 american thoracic society (ats) international conference

DURHAM, N.C., May 11, 2023 (GLOBE NEWSWIRE) — Aerami Therapeutics (“Aerami”), a clinical stage biopharmaceutical company dedicated to breathing ...

May 11, 2023, 12:00 pm

Fluid therapy market showing tremendous growth globally by 2023-2028| research report by leading players

cardiopulmonary Wake (CPR), Congestive Heart Failure (CHF), Infusion, Hypertonic Saline, Other) that wi...

January 27, 2023, 12:14 pm


Search within

Pages Search Results: